Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

ATRA

Atara Biotherapeutics Inc

May 06 • 04:00PM ET

0.6298

Dollar change -0.0402
Percentage change -6.00	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN SCHA VTWO VHT IWC FESM IWO

Index	RUT	P/E	-	EPS (ttm)	-2.61	Insider Own	7.74%	Shs Outstand	119.36M	Perf Week	-11.82%
Market Cap	75.17M	Forward P/E	-	EPS next Y	-0.40	Insider Trans	8.23%	Shs Float	110.12M	Perf Month	-18.64%
Income	-276.13M	PEG	-	EPS next Q	-0.26	Inst Own	59.63%	Short Float	10.39%	Perf Quarter	-43.26%
Sales	8.57M	P/S	8.77	EPS this Y	79.08%	Inst Trans	-0.35%	Short Ratio	6.62	Perf Half Y	-47.08%
Book/sh	-0.93	P/B	-	EPS next Y	26.01%	ROA	-101.91%	Short Interest	11.45M	Perf Year	-77.10%
Cash/sh	0.43	P/C	1.45	EPS next 5Y	-	ROE	-2014.86%	52W Range	0.20 - 3.02	Perf YTD	22.82%
Dividend Est.	2.00 (317.56%)	P/FCF	-	EPS past 5Y	13.12%	ROI	-	52W High	-79.11%	Beta	0.57
Dividend TTM	-	Quick Ratio	0.65	Sales past 5Y	25.21%	Gross Margin	-99.79%	52W Low	217.12%	ATR (14)	0.06
Dividend Ex-Date	-	Current Ratio	0.72	EPS Y/Y TTM	-16.73%	Oper. Margin	-3140.98%	RSI (14)	39.37	Volatility	10.50% 8.44%
Employees	225	Debt/Eq	-	Sales Y/Y TTM	-86.51%	Profit Margin	-3220.88%	Recom	2.60	Target Price	4.20
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	22.66%	Payout	-	Rel Volume	0.60	Prev Close	0.67
Sales Surprise	65.96%	EPS Surprise	-25.84%	Sales Q/Q	1823.98%	Earnings	Mar 28 BMO	Avg Volume	1.73M	Price	0.63
SMA20	-10.04%	SMA50	-10.82%	SMA200	-39.73%	Trades		Volume	1,145,126	Change	-6.00%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-09-23	Downgrade	Mizuho	Buy → Neutral	$31 → $1
Nov-09-23	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-09-23	Downgrade	Evercore ISI	Outperform → In-line
Jul-20-22	Downgrade	Citigroup	Neutral → Sell	$8 → $3
Jul-13-22	Downgrade	Stifel	Buy → Hold	$16 → $5
Jul-13-22	Downgrade	JP Morgan	Overweight → Neutral	$10
May-10-22	Downgrade	Citigroup	Buy → Neutral	$15 → $8
May-13-21	Upgrade	JP Morgan	Neutral → Overweight	$23 → $29
Dec-09-20	Downgrade	Citigroup	Buy → Neutral	$20 → $27
Dec-08-20	Reiterated	H.C. Wainwright	Buy	$28 → $31
Nov-10-20	Reiterated	H.C. Wainwright	Buy	$26 → $28
Jun-30-20	Initiated	Evercore ISI	Outperform
Jun-15-20	Initiated	H.C. Wainwright	Buy	$25
Apr-23-20	Upgrade	Citigroup	Neutral → Buy	$14
Nov-08-19	Downgrade	JP Morgan	Overweight → Neutral	$43 → $22
Sep-27-19	Downgrade	Goldman	Neutral → Sell	$14 → $9
Sep-16-19	Downgrade	Jefferies	Buy → Hold	$32 → $15
Jun-04-19	Upgrade	Citigroup	Sell → Neutral	$23 → $24
May-30-19	Initiated	ROTH Capital	Buy
May-23-19	Initiated	Stifel	Buy

Show Previous Ratings

May-03-24 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-05-24 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-28-24 01:53PM	ATRA Stock Earnings: Atara Biotherapeutics Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
09:40AM	Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:40AM	Atara Biotherapeutics: Q4 Earnings Snapshot (Associated Press Finance)
08:30AM	Loading…
08:30AM	Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress (Business Wire)
Feb-29-24 09:05AM	Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy (Business Wire)
Feb-28-24 04:30PM	Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference (Business Wire)
Feb-14-24 09:00AM	Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis (Business Wire)
Jan-31-24 06:30PM	Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel Data in The Lancet Oncology (Business Wire)
Jan-11-24 01:26AM	Seth Klarman's Firm Exits Atara Biotherapeutics Inc Holding (GuruFocus.com) +5.31%
01:26AM	Seth Klarman's Exit from Atara Biotherapeutics Inc (GuruFocus.com)
Jan-08-24 09:00AM	Atara Biotherapeutics Announces $15 Million Registered Direct Offering (Business Wire) +25.28%
08:00AM	Atara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Jan-04-24 04:01PM	Atara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
04:01PM	Loading…
Dec-20-23 04:01PM	Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel Partnership with Pierre Fabre Laboratories (Business Wire)
Dec-11-23 12:00PM	Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting (Business Wire)
Dec-01-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-29-23 06:05PM	Atara Biotherapeutics To Present Positive New Tab-cel Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023 (Business Wire) +13.36%
Nov-24-23 12:29PM	Atara Biotherapeutics (ATRA) Slumps 57% in a Month: Here's Why (Zacks) +13.93%
Nov-22-23 04:01PM	Atara Biotherapeutics to Participate at the 6th Annual Evercore ISI HealthCONx Conference (Business Wire) +13.22%
09:14AM	Billionaire Seth Klarmans Biotech Stock Picks (Insider Monkey)
Nov-10-23 04:01PM	Atara Biotherapeutics To Participate at the Stifel Healthcare Conference (Business Wire)
Nov-09-23 08:23AM	Why Is Atara Biotherapeutics (ATRA) Stock Down 50% Today? (InvestorPlace) -80.17%
06:40AM	Ataras cell therapy approach to MS falls short in study (BioPharma Dive)
Nov-08-23 05:35PM	Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis (Business Wire) -9.02%
Nov-05-23 12:50PM	Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-02-23 05:42AM	Atara Biotherapeutics Inc (ATRA) Announces Q3 2023 Financial Results and Expanded Global Partnership (GuruFocus.com) -5.56%
02:25AM	Q3 2023 Atara Biotherapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-01-23 08:35AM	Atara Biotherapeutics: Q3 Earnings Snapshot (Associated Press Finance)
08:30AM	Loading…
08:30AM	Atara Biotherapeutics Announces Expanded Global Tab-cel Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results (Business Wire)
Oct-06-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-21-23 09:19AM	Atara (ATRA) Up 11% on Regulatory Update From Blood Cancer Study (Zacks)
Sep-19-23 04:01PM	Atara Biotherapeutics Announces Plans to Submit Tab-cel® BLA in Q2 2024 Following FDA Agreement on Comparability (Business Wire)
Sep-01-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.16%
Aug-31-23 04:01PM	Atara Biotherapeutics to Participate in Cell Therapies in Autoimmune Panel Discussion at the Citi 18th Annual BioPharma Conference (Business Wire)
Aug-13-23 10:44AM	10 Most Promising Penny Stocks According to Analysts (Insider Monkey)
Aug-08-23 05:30PM	Atara Biotherapeutics (ATRA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:18PM	Atara Biotherapeutics: Q2 Earnings Snapshot (AP Finance)
04:01PM	Atara Biotherapeutics Announces Second Quarter 2023 Financial Results and Operational Progress (Business Wire)
Aug-04-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-01-23 04:01PM	Atara Biotherapeutics to Announce Second Quarter 2023 Financial Results on Tuesday, August 8, 2023 (Business Wire)
Jul-31-23 04:01PM	Atara Biotherapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference (Business Wire) +7.28%
Jul-29-23 11:07AM	10 Stocks That Will Go Up 1000 Percent (Insider Monkey)
Jul-17-23 07:29AM	3 Doomed Biotech Stocks Destined for Disaster (InvestorPlace) +6.56%
Jul-07-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +11.45%
Jun-16-23 06:05AM	Time To Worry? Analysts Just Downgraded Their Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Outlook (Simply Wall St.) -6.07%
Jun-07-23 04:01PM	Atara Biotherapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference (Business Wire)
Jun-05-23 09:00AM	Atara Biotherapeutics Presents Updated Tab-cel® Clinical Effectiveness Data at ASCO 2023 (Business Wire)
Jun-02-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-18-23 07:09AM	Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Analysts Are More Bearish Than They Used To Be (Simply Wall St.)
May-08-23 05:15PM	Atara Biotherapeutics (ATRA) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:12PM	Atara Biotherapeutics: Q1 Earnings Snapshot (AP Finance)
04:01PM	Atara Biotherapeutics Announces First Quarter 2023 Financial Results and Operational Progress (Business Wire)
May-07-23 08:59AM	The Market Doesn't Like What It Sees From Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Revenues Yet (Simply Wall St.)
May-05-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.82%
May-01-23 04:01PM	Atara Biotherapeutics to Announce First Quarter 2023 Financial Results on Monday, May 8, 2023 (Business Wire)
Apr-16-23 12:08PM	3 Stocks to Buy That Could Be the Next Biotech Breakthrough (InvestorPlace)
Mar-31-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-24-23 09:35AM	Atara Biotherapeutics (ATRA) Loses -33.02% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Mar-03-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
09:40AM	Are Medical Stocks Lagging Apexigen, Inc. (APGN) This Year? (Zacks)
Mar-01-23 04:01PM	Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 43rd Annual Health Care Conference (Business Wire)
Feb-21-23 04:01PM	Atara Biotherapeutics to Participate in the H.C. Wainwright Cell Therapy Virtual Conference (Business Wire) -9.96%
Feb-15-23 06:58AM	The past five years for Atara Biotherapeutics (NASDAQ:ATRA) investors has not been profitable (Simply Wall St.)
Feb-08-23 05:15PM	Atara Biotherapeutics (ATRA) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -7.69%
04:01PM	Atara Biotherapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress (Business Wire)
06:00AM	Pierre Fabre to Commercialize and Distribute the First Approved Allogeneic T-cell Immunotherapy in Europe Following Transfer of the European Commission Marketing Authorization of EBVALLO (tabelecleucel) (Business Wire)
Feb-06-23 08:00AM	Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on Wednesday, February 8, 2023 (Business Wire)
Feb-03-23 04:01PM	Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.31%
Jan-13-23 04:01PM	Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-04-23 04:01PM	Atara Biotherapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-24-22 10:07AM	3 Under-the-Radar Biotech Stocks to Buy in 2022 (Motley Fool)
Dec-20-22 04:33PM	Atara Biotherapeutics Announces $31 Million Royalty Interest Financing Agreement with HealthCare Royalty (Business Wire)
Dec-19-22 08:00AM	Atara Biotherapeutics Announces Changes to Its Board of Directors (Business Wire)
07:00AM	Atara Biotherapeutics Ebvallo (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLD (Business Wire)
Dec-15-22 04:01PM	Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -10.82%
Dec-12-22 10:00AM	Atara Biotherapeutics Presents Updated Clinical Data from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 64th American Society of Hematology (ASH) Annual Meeting (Business Wire)
Dec-02-22 04:01PM	Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +8.18%
Nov-23-22 08:00AM	Atara Biotherapeutics to Participate at the Evercore ISI 5th Annual HealthCONx Conference (Business Wire)
Nov-22-22 05:03AM	Newsflash: Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Analysts Have Been Trimming Their Revenue Forecasts (Simply Wall St.)
Nov-10-22 05:52AM	Atara Biotherapeutics Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS In Line (Simply Wall St.) +23.97%
Nov-09-22 04:01PM	Atara Biotherapeutics to Participate at the Stifel Healthcare Conference (Business Wire) -20.82%
Nov-08-22 05:15PM	Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Atara Biotherapeutics Announces Third Quarter 2022 Financial Results and Operational Progress (Business Wire)
Nov-04-22 04:01PM	Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-01-22 04:05PM	Atara Biotherapeutics to Announce Third Quarter 2022 Financial Results on Tuesday, November 8, 2022 (Business Wire)
Oct-26-22 02:01AM	Atara Biotherapeutics Presents New MRI and Updated Open-Label Extension Data from Phase 1 Study of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2022 (Business Wire)
Oct-14-22 07:08AM	CHMP Recommends Approval of Atara Biotherapeutics Ebvallo (tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (Business Wire) -6.52%
Oct-13-22 12:51PM	BioMarin (BMRN) Hemophilia Gene Therapy BLA Gets FDA Acceptance (Zacks)
Oct-10-22 04:01PM	Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-07-22 10:01AM	Allogene (ALLO) Begins Phase II Study on Allogeneic CAR T Therapy (Zacks) -8.61%
Oct-06-22 01:36PM	Acadia (ACAD) Rises More Than 14% in 3 Months: Here's Why (Zacks)
Sep-30-22 08:59AM	Horizon (HZNP) Completes Enrollment in Phase IV TED Study (Zacks)
Sep-29-22 11:09AM	Sanofi's (SNY) Dupixent Gets FDA Nod for Prurigo Nodularis (Zacks) -5.47%
07:30AM	Atara Biotherapeutics to Receive Additional Near-Term Milestone Under Updated Tab-cel Commercialization Pact (Benzinga)
Sep-28-22 04:01PM	Atara Biotherapeutics to Receive Additional Near-Term Milestone Payment Under Updated Tabelecleucel (Tab-cel®) Commercialization Agreement with Pierre Fabre (Business Wire) +15.32%
01:47PM	Merck's (MRK) Keytruda Gets Four New Approvals in Japan (Zacks)
Sep-27-22 10:13AM	Emergent (EBS) Acquires Worldwide Rights to Smallpox Antiviral (Zacks)
Sep-21-22 06:32PM	Alnylam's (ALNY) Rare Disease Drug Amvuttra Gets EC Nod (Zacks) -5.53%

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Touchon Pascal	President and CEO	Mar 04 '24	Sale	0.72	24,844	17,888	1,910,652	Mar 06 06:19 PM
Nguyen AnhCo	EVP, Chief Sci. & Tech Officer	Mar 04 '24	Sale	0.72	10,746	7,737	941,397	Mar 06 06:18 PM
Murugan Amar	EVP, Chief Legal Officer	Mar 04 '24	Sale	0.72	10,044	7,232	727,521	Mar 06 06:18 PM
Henrich Jill	EVP, Global Head RA & Quality	Mar 04 '24	Sale	0.72	3,879	2,793	555,001	Mar 06 06:16 PM
Touchon Pascal	President and CEO	Nov 16 '23	Sale	0.39	20,409	7,939	655,496	Nov 20 05:31 PM
Joshi Manher	EVP, Chief Medical Officer	Nov 16 '23	Sale	0.39	12,287	4,780	171,284	Nov 20 05:30 PM
Hyllengren Eric J	SVP, CFO	Nov 16 '23	Sale	0.39	11,958	4,652	205,998	Nov 20 05:29 PM
Nguyen AnhCo	EVP, Chief Sci. & Tech Officer	Nov 16 '23	Sale	0.39	8,856	3,445	277,143	Nov 20 05:31 PM
Murugan Amar	EVP, Chief Legal Officer	Nov 16 '23	Sale	0.39	8,307	3,231	257,084	Nov 20 05:30 PM
Henrich Jill	EVP, Global Head RA & Quality	Nov 16 '23	Sale	0.39	3,267	1,271	104,424	Nov 20 05:29 PM
Gallagher Carol Giltner	Director	Nov 14 '23	Buy	0.31	90,980	28,186	459,418	Nov 15 05:07 PM
Gallagher Carol Giltner	Director	Nov 13 '23	Buy	0.22	179,020	40,029	368,438	Nov 15 05:07 PM
DOBMEIER ERIC	Director	Nov 10 '23	Buy	0.23	446,825	101,340	563,325	Nov 14 06:27 PM
HEIDEN WILLIAM K	Director	Nov 10 '23	Buy	0.25	100,000	25,330	209,000	Nov 14 06:29 PM
Touchon Pascal	President and CEO	Aug 16 '23	Sale	1.65	30,766	50,835	675,905	Aug 18 06:25 PM
Nguyen AnhCo	EVP, Chief Sci. & Tech Officer	Aug 16 '23	Sale	1.65	15,126	24,997	285,999	Aug 18 06:25 PM
Murugan Amar	EVP, Chief Legal Officer	Aug 16 '23	Sale	1.65	8,672	14,330	265,391	Aug 18 06:25 PM
Hyllengren Eric J	SVP, CFO	Aug 16 '23	Sale	1.65	8,186	13,527	217,956	Aug 18 06:25 PM
Joshi Manher	EVP, Chief Medical Officer	Aug 16 '23	Sale	1.65	6,975	11,526	183,571	Aug 18 06:25 PM
Henrich Jill	EVP, Global Head RA & Quality	Aug 16 '23	Sale	1.65	3,346	5,531	107,691	Aug 18 06:25 PM
Touchon Pascal	President and CEO	Jun 27 '23	Sale	1.66	14,291	23,723	706,671	Jun 29 04:15 PM
Touchon Pascal	President and CEO	May 16 '23	Sale	2.04	29,766	60,633	720,962	May 18 08:17 PM
Banard Charlene A.	EVP, Chief Technical Officer	May 16 '23	Sale	2.04	19,040	38,784	276,010	May 18 08:17 PM
Murugan Amar	EVP, Chief Legal Officer	May 16 '23	Sale	2.04	8,389	17,089	270,945	May 18 08:17 PM
Hyllengren Eric J	SVP, CFO	May 16 '23	Sale	2.04	7,918	16,131	226,142	May 18 08:17 PM

Open in Screener

CCCC

C4 Therapeutics Inc

May 06 • 04:00PM ET

6.71

Dollar change -0.03
Percentage change -0.45	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

CCCC C4 Therapeutics Inc daily Stock Chart

Held by: VTI VXF LABU SCHA DFAT DFAS DFAC IWC AVSC ITOT

Index	-	P/E	-	EPS (ttm)	-2.67	Insider Own	15.88%	Shs Outstand	60.47M	Perf Week	6.17%
Market Cap	461.72M	Forward P/E	-	EPS next Y	-1.88	Insider Trans	0.00%	Shs Float	57.88M	Perf Month	-10.77%
Income	-132.49M	PEG	-	EPS next Q	-0.36	Inst Own	71.61%	Short Float	16.52%	Perf Quarter	26.60%
Sales	20.76M	P/S	22.24	EPS this Y	30.76%	Inst Trans	-1.55%	Short Ratio	4.24	Perf Half Y	379.29%
Book/sh	4.07	P/B	1.65	EPS next Y	-1.95%	ROA	-32.82%	Short Interest	9.56M	Perf Year	107.74%
Cash/sh	3.69	P/C	1.82	EPS next 5Y	22.30%	ROE	-49.50%	52W Range	1.06 - 11.88	Perf YTD	18.76%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-36.05%	ROI	-42.48%	52W High	-43.52%	Beta	3.23
Dividend TTM	-	Quick Ratio	6.34	Sales past 5Y	7.65%	Gross Margin	62.72%	52W Low	533.02%	ATR (14)	0.44
Dividend Ex-Date	-	Current Ratio	6.34	EPS Y/Y TTM	-1.78%	Oper. Margin	-669.84%	RSI (14)	42.79	Volatility	5.52% 5.66%
Employees	145	Debt/Eq	0.29	Sales Y/Y TTM	-33.25%	Profit Margin	-638.34%	Recom	1.67	Target Price	17.22
Option/Short	Yes / Yes	LT Debt/Eq	0.27	EPS Q/Q	10.64%	Payout	-	Rel Volume	0.52	Prev Close	6.74
Sales Surprise	1.92%	EPS Surprise	1.00%	Sales Q/Q	14.26%	Earnings	Feb 22 BMO	Avg Volume	2.25M	Price	6.71
SMA20	-2.55%	SMA50	-19.57%	SMA200	42.21%	Trades		Volume	1,182,769	Change	-0.45%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-29-24	Upgrade	JP Morgan	Underweight → Neutral	$6
Dec-13-23	Upgrade	Stifel	Hold → Buy	$2 → $12
Feb-24-23	Upgrade	Credit Suisse	Underperform → Neutral	$12 → $10
Feb-24-23	Downgrade	JP Morgan	Neutral → Underweight	$15 → $5
Nov-04-22	Downgrade	JP Morgan	Overweight → Neutral	$22 → $15
Oct-11-22	Initiated	Morgan Stanley	Underweight	$6
Apr-28-22	Initiated	Credit Suisse	Underperform	$10
Apr-11-22	Downgrade	BofA Securities	Buy → Neutral	$46 → $15
Mar-10-22	Initiated	JP Morgan	Overweight	$43
Feb-11-22	Resumed	BMO Capital Markets	Outperform	$57
Feb-10-22	Initiated	Wells Fargo	Equal Weight	$25
Nov-23-21	Initiated	BofA Securities	Buy	$54
Oct-14-21	Initiated	SVB Leerink	Mkt Perform	$20
Sep-30-21	Initiated	Stifel	Hold	$45
Jun-04-21	Initiated	H.C. Wainwright	Buy	$63
Mar-31-21	Initiated	BMO Capital Markets	Outperform	$55
Oct-28-20	Initiated	UBS	Buy	$44
Oct-27-20	Initiated	Jefferies	Buy	$34
Oct-27-20	Initiated	BMO Capital Markets	Outperform	$33

Show Previous Ratings

Apr-29-24 04:01PM	C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-09-24 07:00AM	C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum (GlobeNewswire)
Apr-08-24 08:00AM	C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024 (GlobeNewswire)
Mar-28-24 04:36AM	Here's Why Meridian Small Cap Growth Fund Trimmed C4 Therapeutics (CCCC) (Insider Monkey)
Mar-05-24 04:30PM	C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC Degraders at the American Association for Cancer Research Annual Meeting 2024 (GlobeNewswire)
07:00AM	Loading…
Mar-04-24 07:00AM	C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins (GlobeNewswire)
Feb-22-24 08:15AM	C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +21.38%
07:36AM	C4 Therapeutics Inc (CCCC) Reports Full Year 2023 Financial Results and Business Updates (GuruFocus.com)
07:00AM	C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Feb-15-24 10:19AM	C4 Therapeutics (CCCC) to Report Q4 Earnings: What's in Store? (Zacks) +8.07%
10:00AM	C4 Therapeutics, Inc. (CCCC) May Report Negative Earnings: Know the Trend Ahead of Q4 Release (Zacks)
Jan-11-24 11:44AM	C4 (CCCC) Up 6% on Restructuring Plan to Curb Cash Burn (Zacks) -5.97%
Jan-09-24 06:20PM	C4 Therapeutics, Inc. (CCCC)'s Technical Outlook is Bright After Key Golden Cross (Zacks) +6.90%
04:01PM	C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines (GlobeNewswire)
Jan-04-24 04:01PM	C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals (GlobeNewswire) +9.69%
07:00AM	Loading…
07:00AM	C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-03-24 11:10AM	C4 Therapeutics (CCCC) Gains 310% in 3 Months: Here's Why (Zacks) -11.35%
Jan-01-24 09:55AM	Wall Street Analysts See a 197.7% Upside in C4 Therapeutics, Inc. (CCCC): Can the Stock Really Move This High? (Zacks)
Dec-27-23 07:35PM	11 Hot Healthcare Stocks To Buy Now (Insider Monkey)
Dec-15-23 09:55AM	Wall Street Analysts Think C4 Therapeutics, Inc. (CCCC) Could Surge 222.95%: Read This Before Placing a Bet (Zacks)
Dec-13-23 12:39PM	C4 Therapeutics (CCCC) Soars on Oncology Deal With Merck (Zacks) +135.47%
Dec-12-23 04:01PM	C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma (GlobeNewswire) +98.31%
10:13AM	Why Is C4 Therapeutics (CCCC) Stock Up 72% Today? (InvestorPlace)
07:00AM	C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs) (GlobeNewswire)
Nov-28-23 07:00AM	C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma (GlobeNewswire)
Nov-20-23 07:00AM	C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment (GlobeNewswire) -6.63%
Nov-13-23 09:55AM	Here's Why C4 Therapeutics, Inc. (CCCC) Looks Ripe for Bottom Fishing (Zacks)
Nov-01-23 11:03AM	C4 Therapeutics discontinues cancer program, waits for Betta payment (FierceBiotech.com) -11.41%
09:40AM	C4 Therapeutics Inc (CCCC) Reports Q3 2023 Financial Results and Business Highlights (GuruFocus.com)
07:00AM	C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
07:00AM	Loading…
Oct-11-23 07:00AM	C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC Degrader in Development for Multiple Myeloma and Non-Hodgkin's Lymphoma (GlobeNewswire)
Sep-05-23 04:01PM	C4 Therapeutics Announces Chief Financial Officer Succession (GlobeNewswire) -7.29%
Aug-28-23 06:30PM	12 Best High Risk Penny Stocks to Buy Now (Insider Monkey)
Aug-08-23 08:40AM	C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Aug-04-23 06:58AM	With 64% institutional ownership, C4 Therapeutics, Inc. (NASDAQ:CCCC) is a favorite amongst the big guns (Simply Wall St.)
Jul-17-23 07:00AM	C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-05-23 07:00AM	C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT8919, an Orally Bioavailable BiDAC Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer (GlobeNewswire) +17.31%
Jun-20-23 07:00AM	C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer (GlobeNewswire) -7.72%
May-30-23 07:00AM	C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC Degrader of EGFR L858R for NSCLC (GlobeNewswire) +8.77%
May-14-23 08:06AM	Broker Revenue Forecasts For C4 Therapeutics, Inc. (NASDAQ:CCCC) Are Surging Higher (Simply Wall St.)
May-04-23 08:15AM	C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-19-23 07:00AM	C4 Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days (GlobeNewswire)
Apr-11-23 09:35AM	Down -29.73% in 4 Weeks, Here's Why You Should You Buy the Dip in C4 Therapeutics, Inc. (CCCC) (Zacks)
Mar-23-23 07:39AM	Insiders who bought this year lost US$59k as C4 Therapeutics, Inc. (NASDAQ:CCCC) sheds US$27m in value (Simply Wall St.)
Feb-24-23 05:38AM	C4 Therapeutics Full Year 2022 Earnings: Misses Expectations (Simply Wall St.) -11.46%
Feb-23-23 08:35AM	C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:00AM	C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights (GlobeNewswire)
Feb-08-23 07:00AM	C4 Therapeutics to Present at Two Virtual February 2023 Conferences (GlobeNewswire) -5.86%
Jan-30-23 07:00AM	C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDAC Degrader, in BRAF V600 Mutant Solid Tumors (GlobeNewswire)
Jan-09-23 07:00AM	C4 Therapeutics Announces 2023 Strategic Priorities to Advance Portfolio of Targeted Protein Degradation Medicines (GlobeNewswire) +6.40%
Jan-05-23 06:15PM	C4 Therapeutics, Inc. (CCCC) Dips More Than Broader Markets: What You Should Know (Zacks)
Jan-04-23 09:40AM	Are Medical Stocks Lagging AMN Healthcare Services (AMN) This Year? (Zacks)
Jan-03-23 07:00AM	C4 Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +8.14%
Nov-13-22 07:13AM	The past year for C4 Therapeutics (NASDAQ:CCCC) investors has not been profitable (Simply Wall St.)
Nov-08-22 09:55AM	Wall Street Analysts Think C4 Therapeutics, Inc. (CCCC) Could Surge 227%: Read This Before Placing a Bet (Zacks)
Nov-03-22 08:25AM	C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:00AM	C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-02-22 10:01AM	C4 Therapeutics, Inc. (CCCC) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks) -5.27%
Oct-03-22 09:02AM	One C4 Therapeutics, Inc. (NASDAQ:CCCC) insider upped their stake in the previous year (Simply Wall St.)
Sep-29-22 07:00AM	C4 Therapeutics Receives Study May Proceed Letter from U.S. FDA to Initiate Phase 1/2 Clinical Trial of CFT1946, an Orally Bioavailable BiDAC Degrader, in BRAF-V600 Mutant Solid Cancers (GlobeNewswire) -5.01%
Sep-26-22 07:00AM	C4 Therapeutics to Present at Bank of America Securities Precision Oncology Conference 2022 (GlobeNewswire)
Sep-06-22 08:22AM	With 63% ownership of the shares, C4 Therapeutics, Inc. (NASDAQ:CCCC) is heavily dominated by institutional owners (Simply Wall St.)
Aug-10-22 06:05AM	Growth Investors: Industry Analysts Just Upgraded Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Revenue Forecasts By 16% (Simply Wall St.)
Aug-07-22 08:21AM	Analysts Are Upgrading C4 Therapeutics, Inc. (NASDAQ:CCCC) After Its Latest Results (Simply Wall St.)
Aug-04-22 09:15AM	C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +6.95%
08:00AM	C4 Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire)
Aug-02-22 08:00AM	C4 Therapeutics Appoints Experienced Clinical Development Leaders Laura Bessen, M.D. and Donna Grogan, M.D. to Board of Directors (GlobeNewswire) +6.01%
May-16-22 08:00AM	C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDAC Degrader for the Treatment of Synovial Sarcoma and SMARCB1-null Tumors (GlobeNewswire) -6.15%
May-05-22 09:15AM	C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
08:00AM	C4 Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-08-22 02:15PM	C4 Therapeutics Stock Falls On CFT7455 Dose Limiting Toxicity In Multiple Myeloma Trial (Benzinga) -50.57%
01:00PM	C4 Therapeutics Presents Clinical Data from Cohort A of the Ongoing Phase 1/2 Clinical Trial of CFT7455, a Novel IKZF1/3 Degrader (GlobeNewswire)
10:05AM	Investors one-year losses grow to 32% as the stock sheds US$66m this past week (Simply Wall St.)
Mar-17-22 11:44AM	J.P. Morgan Says Theres Room for Over 80% Gains in These 2 Stocks (TipRanks) +5.92%
Mar-16-22 04:05PM	C4 Therapeutics Appoints Utpal Koppikar to Board of Directors (GlobeNewswire) +5.30%
Mar-09-22 08:00AM	C4 Therapeutics Announces FDA Orphan Drug Designation for CFT8634 for the Treatment of Soft Tissue Sarcoma (GlobeNewswire) +15.29%
Mar-08-22 04:30PM	C4 Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2022 (GlobeNewswire)
Feb-24-22 07:00AM	C4 Therapeutics Reports Full Year 2021 Financial Results and Recent Business Highlights (GlobeNewswire) +13.96%
Feb-07-22 04:45AM	What Is The Ownership Structure Like For C4 Therapeutics, Inc. (NASDAQ:CCCC)? (Simply Wall St.)
Jan-12-22 11:09AM	Is C4 Therapeutics, Inc. (CCCC) A Good Stock To Buy? (Insider Monkey)
Jan-10-22 07:00AM	C4 Therapeutics Announces 2022 Key Milestones to Advance Targeted Protein Degradation Portfolio (GlobeNewswire) +8.52%
Jan-03-22 07:00AM	C4 Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-29-21 12:00PM	What Makes C4 Therapeutics, Inc. (CCCC) a New Buy Stock (Zacks)
Dec-17-21 08:00AM	C4 Therapeutics Added to NASDAQ Biotechnology Index (GlobeNewswire)
Dec-01-21 07:28AM	C4 Therapeutics (CCCC) Sees Hammer Chart Pattern: Time to Buy? (Zacks) -7.35%
Nov-22-21 12:00PM	C4 Therapeutics, Inc. (CCCC) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Nov-10-21 04:01PM	C4 Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Results (GlobeNewswire)
08:34AM	Why C4 Therapeutics (CCCC) Might Surprise This Earnings Season (Zacks)
Oct-26-21 10:41AM	Hedge Funds Are Piling Into C4 Therapeutics, Inc. (CCCC) (Insider Monkey)
Oct-09-21 09:14AM	C4 Therapeutics (NASDAQ:CCCC) pulls back 8.2% this week, but still delivers shareholders notable 85% return over 1 year (Simply Wall St.)
Sep-17-21 10:27AM	Director Of C4 Therapeutics Sold $3.98 Million In Stock (Benzinga)
Aug-11-21 04:02PM	C4 Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results (GlobeNewswire)
04:01PM	C4 Therapeutics Announces FDA Orphan Drug Designation for CFT7455 for the Treatment of Multiple Myeloma (GlobeNewswire)
Aug-10-21 01:31AM	Is C4 Therapeutics, Inc.'s (NASDAQ:CCCC) Shareholder Ownership Skewed Towards Insiders? (Simply Wall St.)
Jul-21-21 04:24AM	Is C4 Therapeutics, Inc. (CCCC) A Good Stock To Buy Now? (Insider Monkey)
Jul-19-21 01:44PM	C4 Therapeutics Stock Enters Leadership Territory (Investor's Business Daily)
Jun-21-21 04:01PM	C4 Therapeutics Announces Closing of Public Offering and Exercise in Full of the Underwriters Option to Purchase Additional Shares (GlobeNewswire)
08:00AM	C4 Therapeutics Presents Pre-clinical Data on CFT7455, a Novel IKZF1/3 Degrader for the Treatment of Hematologic Malignancies, at the 16th Annual International Conference on Malignant Lymphoma (GlobeNewswire)

C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. It develops the Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Watertown, MA.

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

ATRA

Atara Biotherapeutics Inc

CCCC

C4 Therapeutics Inc

Upgrade your FINVIZ experience